Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment

참고문헌 (103)

1. Waibl Polania, J., "Pushing past the blockade: advancements in T cell-based cancer immunotherapies", Front. Immunol (2021)[DOI]
2. Li, C., "Regulatory T cells in tumor microenvironment : new mechanisms, potential therapeutic strategies and future prospects", Mol. Cancer, 19, pp.116~ (2020)
3. Onda, M., "Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity", Proc. Natl Acad. Sci. USA, 116, pp.4575~4582 (2019)
4. Zammarchi, F., "CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity", J. Immunother. Cancer, 8, pp.e000860~ (2020)
5. Labani-Motlagh, A., "The tumor microenvironment:a milieu hindering and obstructing antitumor immune responses", Front. Immunol (2020)[DOI]
6. Swann, J. B., "Immune surveillance of tumors", J. Clin. Investig, 117, pp.1137~1146 (2007)
7. Kim, R., "Cancer immunoediting from immune surveillance to immune escape", Immunology, 121, pp.1~14 (2007)
8. O’Donnell, J. S., "Cancer immunoediting and resistance to T cell-based immunotherapy", Nat. Rev. Clin. Oncol, 16, pp.151~167 (2019)
9. Tie, Y., "Immunosuppressive cells in cancer : mechanisms and potential therapeutic targets", J. Hematol. Oncol, 15, pp.61~61 (2022)
10. Tay, C., "Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy", Cancer Cell, 41, pp.450~465 (2023)
11. Nishikawa, H., "Mechanisms of regulatory T cell infiltration in tumors : implications for innovative immune precision therapies", J. Immunother. Cancer, 9, pp.e002591~ (2021)
12. Miyara, M., "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor", Immunity, 30, pp.899~911 (2009)
13. Ohue, Y., "Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?", Cancer Sci, 110, pp.2080~2089 (2019)
14. Flynn, M. J., "ADCT-301, a pyrrolobenzodiazepine(PBD)dimer-containing antibody-drug conjugate(ADC)targeting CD25-expressing hematological malignancies", Mol. Cancer Ther, 15, pp.2709~2721 (2016)
15. Lansigan, F., "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma", Cancer Manag. Res, 2, pp.53~59 (2010)
16. Powell, D. J. Jr., "Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo", J. Immunol, 179, pp.4919~4928 (2007)
17. Herrmann, A., "CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells", J. Clin. Investig, 124, pp.2977~2987 (2014)
18. Li, S. -Y., "Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation", J. Control. Release, 231, pp.17~28 (2016)
19. Zhang, J., "Hybrid spherical nucleotide nanoparticles can enhance the synergistic anti-tumor effect of CTLA-4 and PD-1 blockades", Biomater. Sci, 8, pp.4757~4766 (2020)
20. Campbell, J. R., "Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models", Cancer Res, 81, pp.2983~2994 (2021)
21. De Simone, M., "Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells", Immunity, 45, pp.1135~1147 (2016)
22. Plitas, G., "Regulatory T cells exhibit distinct features in human breast cancer", Immunity, 45, pp.1122~1134 (2016)
23. Guo, X., "Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing", Nat. Med, 24, pp.978~985 (2018)
24. Zhang, Y., "Deep single-cell RNA sequencing data of individual T cells from treatment-naïve colorectal cancer patients", Sci. Data, 6, pp.131~ (2019)
25. Cinier, J., "Recruitment and expansion of tregs cells in the tumor environment—how to target them?", Cancers, 13, pp.1850~ (2021)
26. Hori, S., "Control of regulatory T cell development by the transcription factor Foxp3", Science, 299, pp.1057~1061 (2003)
27. Allan, S. E., "Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3", Mol. Ther, 16, pp.194~202 (2008)
28. Manrique-Rincón, A. J., "Aptamer-mediated transcriptional gene silencing of Fox p 3 inhibits regulatory T cells and potentiates antitumor response", Mol. Ther. Nucleic Acids, 25, pp.143~151 (2021)
29. Lozano, T., "Searching for peptide inhibitors of T regulatory cell activity by targeting specific domains of FOXP3 transcription factor", Biomedicines (2021)[DOI]
30. Xu, P., "Screening of specific binding peptides using phage-display techniques and their biosensing applications", TrAC Trends Anal. Chem, 137, pp.116229~ (2021)
31. Yongsheng, Y., "siRNA-mediated knockdown of FoxP3 promotes the ratio of T-helper 1(Th1)to Th2 in chronic hepatitis B patients", Turk. J. Gastroenterol, 22, pp.587~593 (2011)
32. Amarzguioui, M., "Rational design and in vitro and in vivo delivery of Dicer substrate siRNA", Nat. Protoc, 1, pp.508~517 (2006)
33. Strebhardt, K., "Paul Ehrlich’s magic bullet concept : 100 years of progress", Nat. Rev. Cancer, 8, pp.473~480 (2008)
34. Fu, Z., "Antibody drug conjugate : the"biological missile"for targeted cancer therapy", Signal Transduct. Target. Ther, 7, pp.93~ (2022)
35. Jung-Ho Kim, "Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy", Immune Network, 20(1), pp.1~17 (2020), 대한면역학회[DOI]
36. Coleman, N., "Antibody-drug conjugates in lung cancer: dawn of a new era?", npj Precis. Oncol, 7, pp.5~ (2023)
37. McKertish, C. M., "Advances and limitations of antibody drug conjugates for cancer", Biomedicines (2021)[DOI]
38. Lambert, J. M., "Antibody–drug conjugates(ADCs)for personalized treatment of solid tumors : a review", Adv. Ther, 34, pp.1015~1035 (2017)
39. Smith, A. L., "The enediyne antibiotics", J. Med. Chem, 39, pp.2103~2117 (1996)
40. Pommier, Y., "Topoisomerase I inhibitors : camptothecins and beyond", Nat. Rev. Cancer, 6, pp.789~802 (2006)
41. Francisco, J. A., "cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity", Blood, 102, pp.1458~1465 (2003)
42. Oroudjev, E., "Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability", Mol. Cancer Ther, 9, pp.2700~2713 (2010)
43. Herrera, A. F., "Preliminary results of a phase 2 study of Camidanlumab Tesirine(Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory hodgkin lymphoma", Blood, 136, pp.21~23 (2020)
44. Hamadani, M., "Camidanlumab tesirine in patients with relapsed or refractory lymphoma : a phase 1, open-label, multicentre, dose-escalation, doseexpansion study", Lancet Haematol, 8, pp.e433~e445 (2021)
45. Goldberg, A. D., "Camidanlumab tesirine, an antibody-drug conjugate, in relapsed", refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia : a phase I study, 2020, pp.95, 106385~
46. Kim, J. -S., "Critical issues in the development of immunotoxins for anticancer therapy", J. Pharm. Sci, 109, pp.104~115 (2020)
47. Jen, E. Y., "FDA approval summary : Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm", Clin. Cancer Res, 26, pp.532~536 (2020)
48. Lin, A. Y., "Moxetumomab pasudotox for hairy cell leukemia : preclinical development to FDA approval", Blood Adv, 3, pp.2905~2910 (2019)
49. Hamamichi, S., "Immunotoxin screening system: a rapid and direct approach to obtain functional antibodies with internalization capacities", Toxins (Basel) (2020)[DOI]
50. Bruins, W. S. C., "Targeted therapy with immunoconjugates for multiple myeloma", Front Immunol, 11, pp.1155~ (2020)
51. Alewine, C., "Advances in anticancer immunotoxin therapy", Oncologist, 20, pp.176~185 (2015)
52. Li, M., "Strategies to mitigate the on-and offtarget toxicities of recombinant immunotoxins : an antibody engineering perspective", Antib. Ther, 5, pp.164~176 (2022)
53. Kumar, P., "Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy", Immunotherapy, 11, pp.1117~1128 (2019)
54. Attia, P., "Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2", J. Immunother, 29, pp.208~214 (2006)
55. Kreitman, R. J., "Complete remissions of adult T-cell Leukemia with Anti-CD25 recombinant Immunotoxin LMB-2 and chemotherapy to block immunogenicity", Clin. Cancer Res, 22, pp.310~318 (2016)
56. Basheer, F., "Hairy cell leukemia-immunotargets and therapies", Immunotargets Ther, 3, pp.107~120 (2014)
57. Kaminetzky, D., "Denileukin diftitox for the treatment of cutaneous T-cell lymphoma", Biologics, 2, pp.717~724 (2008)
58. Cheung, L. S., "Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma", Proc. Natl Acad. Sci. USA, 116, pp.3100~3105 (2019)
59. )in patients with relapsed or refractory cutaneous T-cell lymphoma : results from pivotal study 302, "Blood", 2022, 1491~1492
60. Kawai, H., "Phase II study of E7777 in Japanese patients with relapsed", refractory peripheral and cutaneous T-cell lymphoma, 2021, pp.112, 2426~2435
61. Chang, D. -K., "Humanization of an Anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells", Mol. Cancer Ther, 11, pp.2451~2461 (2012)
62. Wang, Z., "Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4+ cells in vivo", Mol. Oncol, 9, pp.1458~1470 (2015)
63. Wang, Z., "Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin", Mol. Oncol, 10, pp.553~565 (2016)
64. Wang, H., "Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma", Mol. Oncol, 14, pp.991~1000 (2020)
65. Fu, C., "Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?", Acta Pharmaceut. Sin. B, 13, pp.498~516 (2023)
66. Borsi, L., "Selective targeting of tumoral vasculature : comparison of different formats of an antibody(L19)to the ED-B domain of fibronectin", Int. J. Cancer, 102, pp.75~85 (2002)
67. van Schouwenburg, P. A., "A novel method for the detection of antibodies to adalimumab in the presence of drug reveals"hidden"immunogenicity in rheumatoid arthritis patients", J. Immunol. Methods, 362, pp.82~88 (2010)
68. Carrasco-Triguero, M., "Immunogenicity assays for antibody-drug conjugates : case study with ado-trastuzumab emtansine", Bioanalysis, 5, pp.1007~1023 (2013)
69. Nejadmoghaddam, M. R., "Antibody-drug conjugates : possibilities and challenges", Avicenna J. Med. Biotechnol, 11, pp.3~23 (2019)
70. Ahrens, V. M., "Peptides and peptide conjugates : therapeutics on the upward path", Future Med. Chem, 4, pp.1567~1586 (2012)
71. Firer, M. A., "Targeted drug delivery for cancer therapy : the other side of antibodies", J. Hematol. Oncol, 5, pp.70~ (2012)
72. Alas, M., "Peptide–drug conjugates with different linkers for cancer therapy", J. Med. Chem, 64, pp.216~232 (2021)
73. Chavda, V. P., "Peptide-drug conjugates : a new hope for cancer management", Molecules, 27, pp.7232~ (2022)
74. Kalimuthu, K., "Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells", J. Nanobiotechnol, 16, pp.34~ (2018)
75. Lozano, T., "Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy", Biomaterials, 91, pp.73~80 (2016)
76. Casares, N., "A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice", J. Immunol, 185, pp.5150~5159 (2010)
77. Lozano, T., "Blockage of FOXP3 transcription factor dimerization and FOXP3", AML1 interaction inhibits T regulatory cell activity : sequence optimization of a peptide inhibitor, 2017, pp.8, 71709~71724
78. Pastor, F., "CD28 aptamers as powerful immune response modulators", Mol. Ther. Nucleic Acids, 2, pp.e98~ (2013)
79. Lozano, T., "Targeting inhibition of Foxp3 by a CD28 2’-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy", Biomaterials, 91, pp.73~80 (2016)
80. Lozano, T., "Inhibition of FOXP3", NFAT interaction enhances T cell function after TCR stimulation, 2015, pp.195, 3180~3189
81. Kawamoto, S. A., "Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction", Biochemistry, 48, pp.9534~9541 (2009)
82. Li, X., "WNT", β-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment, 2019, pp.10, 2293~2293
83. Feng, M., "Pharmacological inhibition of β-catenin", BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells, 2019, pp.5, eaau5240~
84. Ezquerro, I. J., "A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury", Cytokine, 22, pp.12~20 (2003)
85. Dotor, J., "Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library", Cytokine, 39, pp.106~115 (2007)
86. Llopiz, D., "Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy", Int. J. Cancer, 125, pp.2614~2623 (2009)
87. Kim, Y. -J., "Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via antiangiogenesis", J. Control. Release, 216, pp.56~68 (2015)
88. Niland, S., "Neuropilins in the context of tumor vasculature", Int. J. Mol. Sci, 20, pp.639~ (2019)
89. Jung, K., "A neuropilin-1 antagonist exerts antitumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells", Cancer Immunol. Res, 8, pp.46~56 (2020)
90. Santagata, S., "Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer", Oncotarget, 8, pp.77110~77120 (2017)
91. Padda, I. S., "StatPearls" (2023), StatPearls Publishing LLC
92. Alshaer, W., "siRNA : mechanism of action, challenges, and therapeutic approaches", Eur. J. Pharmacol, 905, pp.174178~ (2021)
93. Bholakant, R., "Recent advances of polycationic siRNA vectors for cancer therapy", Biomacromolecules, 21, pp.2966~2982 (2020)
94. Dana, H., "Molecular mechanisms and biological functions of siRNA", Int. J. Biomed. Sci, 13, pp.48~57 (2017)
95. Zhang, L., "The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates", Front. Pharmacol (2022)[DOI]
96. Chernikov, I. V., "Current development of siRNA bioconjugates: from research to the clinic", Front. Pharmacol (2019)[DOI]
97. Fu, Z., "Aptamers, the nucleic acid antibodies, in cancer therapy", Int J. Mol. Sci, 21, pp.2793~ (2020)
98. Kruspe, S., "Aptamer-siRNA chimeras: discovery, progress, and future prospects", Biomedicines, 5, pp.45~ (2017)
99. Ashique, S., "siRNA-based nanocarriers for targeted drug delivery to control breast cancer", Adv. Cancer Biol. Metastasis, 4, pp.100047~ (2022)
100. Lee, S. H., "Current preclinical small interfering RNA(siRNA)-based conjugate systems for RNA therapeutics", Adv. Drug Deliv. Rev, 104, pp.78~92 (2016)
101. Shevach, E. M., "CD4+ CD25+ suppressor T cells : more questions than answers", Nat. Rev. Immunol, 2, pp.389~400 (2002)
102. Jia, H., "Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma", Cancer Immunol. Immunother, 61, pp.1977~1987 (2012)
103. Liu, Y., "Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles", J. Control. Release, 192, pp.114~121 (2014)

관련 논문AI추천